Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Ataru Igarashi

Cost-Effectiveness Analysis of Sofosbuvir Plus Ribavirin in Patients With Genotype 2 Chronic Hepatitis C: An Analysis With Real World Outcomes From a Multicentre Cohort in Japan

BMJ Open

Medicine

2019

English

The 14-Item Health Literacy Scale for Japanese Adults (HLS-14)

Environmental Health and Preventive Medicine

English

Related publications

Daclatasvir Plus Sofosbuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Genotype 3a in Pakistani Population - A Real World Experience

Pakistan Journal of Medical Sciences

Medicine

2019

English

Efficacy and Safety of Ribavirin With Sofosbuvir Plus Ledipasvir in Patients With Genotype 1 Hepatitis C: A Meta-Analysis

Digestive Diseases and Sciences

Physiology

Gastroenterology

2016

English

Sofosbuvir Plus Daclatasvir With or Without Ribavirin in 551 Patients With Hepatitis C-Related Cirrhosis, Genotype 4

Alimentary Pharmacology and Therapeutics

English

Cost Effectiveness Analysis of Sofosbuvir and Ledipasvir/Sofosbuvir in Hepatitis C Virus (HCV) Patients

English

Cost-Utility Analysis of Sofosbuvir for Treatment of Genotype2 Chronic Hepatitis C in Japan

English

Ledipasvir / Sofosbuvir for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Across Different Genotype 1 Clinical Subgroups

English

Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection

JAMA - Journal of the American Medical Association

Medicine

2014

English

An Index to Predict Ribavirin-Induced Anemia in Asian Patients With Chronic Genotype 1 Hepatitis C

English

Daclatasvir and Sofosbuvir With Ribavirin for 24 Weeks in Chronic Hepatitis C Genotype-3-Infected Patients With Cirrhosis: A Phase III Study (ALLY-3C)

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Ataru Igarashi

Cost-Effectiveness Analysis of Sofosbuvir Plus Ribavirin in Patients With Genotype 2 Chronic Hepatitis C: An Analysis With Real World Outcomes From a Multicentre Cohort in Japan

The 14-Item Health Literacy Scale for Japanese Adults (HLS-14)

Related publications

Daclatasvir Plus Sofosbuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Genotype 3a in Pakistani Population - A Real World Experience

Efficacy and Safety of Ribavirin With Sofosbuvir Plus Ledipasvir in Patients With Genotype 1 Hepatitis C: A Meta-Analysis

Sofosbuvir Plus Daclatasvir With or Without Ribavirin in 551 Patients With Hepatitis C-Related Cirrhosis, Genotype 4

Cost Effectiveness Analysis of Sofosbuvir and Ledipasvir/Sofosbuvir in Hepatitis C Virus (HCV) Patients

Cost-Utility Analysis of Sofosbuvir for Treatment of Genotype2 Chronic Hepatitis C in Japan

Ledipasvir / Sofosbuvir for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Across Different Genotype 1 Clinical Subgroups

Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection

An Index to Predict Ribavirin-Induced Anemia in Asian Patients With Chronic Genotype 1 Hepatitis C

Daclatasvir and Sofosbuvir With Ribavirin for 24 Weeks in Chronic Hepatitis C Genotype-3-Infected Patients With Cirrhosis: A Phase III Study (ALLY-3C)